Skip to main content
Transcenta Holding Limited logo

Transcenta Holding Limited — Investor Relations & Filings

Ticker · 6628 ISIN · KYG9005B1041 HKEX Manufacturing
Open in API
Filings indexed 482 across all filing types
Latest filing 2026-01-22 Audit Report / Informat…
Country HK Hong Kong
Listing HKEX 6628

About Transcenta Holding Limited

http://www.transcenta.com

Transcenta Holding Limited is a clinical-stage global biotherapeutics company specializing in the discovery, research, development, and manufacturing of differentiated antibody-based therapeutics. The company operates a fully integrated platform, utilizing a unique antibody generation platform based on Immune Tolerance Breaking Technology to generate candidate leads. Its robust pipeline includes therapeutic antibody molecules targeting oncology and selected non-oncology indications, such as bone and kidney disorders. The company employs advanced bioprocessing technologies, including perfusion-based continuous bioprocessing, to accelerate process development and reduce manufacturing costs.

Recent filings

Filing Released Lang Actions
UPDATE ON MEASURES AND ACTIONS TAKEN IN RESOLVING THE DISCLAIMER OF OPINION IN THE ANNUAL REPORT FOR THE YEAR ENDED DECEMBER 31, 2024
Audit Report / Information Classification · 95% confidence The document is an official announcement from Transcenta Holding Limited regarding the progress of measures taken to resolve a 'Disclaimer of Opinion' in their previous annual report. It details specific operational, financial, and strategic updates (licensing, capital funding, CDMO business, etc.) to address regulatory concerns. It is not a full report itself, but a periodic update announcement required by the Stock Exchange of Hong Kong. Given it does not fit into specific categories like 'Earnings Release' or 'Annual Report', and serves as a formal regulatory update, it is classified as a Regulatory Filing. FY 2024
2026-01-22 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025
Share Issue/Capital Change Classification · 95% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in securities, share capital, and treasury shares. Since it is a recurring regulatory filing detailing changes in share structure and does not fit into specific categories like 'Annual Report' or 'Earnings Release', it is classified as a Regulatory Filing (RNS).
2026-01-07 English
GRANT OF AWARD SHARES PURSUANT TO THE SHARE INCENTIVE SCHEME
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from Transcenta Holding Limited regarding the 'Grant of Award Shares' to an employee under their Share Incentive Scheme. It details the number of shares, vesting periods, performance targets, and clawback mechanisms. This type of disclosure, which involves the issuance of new shares or equity-based incentives to employees, falls under the category of share capital changes or equity incentive grants. According to the provided definitions, 'SHA' (Share Issue/Capital Change) is the most appropriate classification for announcements regarding new share issues or equity-based capital changes.
2025-12-29 English
VOLUNTARY ANNOUNCEMENT-TRANSCENTA ANNOUNCES STRATEGIC COLLABORATION AND NON-EXCLUSIVE LICENSING AGREEMENT TO ADVANCE INTEGRATED CONTINUOUS BIOMANUFACTURING AND EXPAND GLOBAL ACCESS TO AFFORDABLE BIOLO
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement from Transcenta Holding Limited regarding a strategic collaboration and non-exclusive licensing agreement for its biomanufacturing platform. It details the nature of the partnership, the technology involved, and the financial expectations (upfront and milestone payments). Since this is a specific corporate announcement regarding a business partnership and licensing deal that does not fit into the other specific categories like M&A or capital raising, it is classified as a general regulatory announcement.
2025-12-29 English
VOLUNTARY ANNOUNCEMENT-TRANSCENTA PRESENTS UPDATED EFFICACY DATA FROM THE PHASE I/II TRANSTAR102 TRIAL OF OSEMITAMAB PLUS NIVOLUMAB AND CAPOX IN FIRST-LINE G/GEJ CANCER AT ESMO ASIA
Regulatory Filings Classification · 98% confidence The document is a voluntary announcement by Transcenta Holding Limited regarding updated clinical trial data (Phase I/II Transtar102) presented at the ESMO Asia Congress. It provides business and clinical updates rather than financial results, governance changes, or regulatory filings. As it does not fit into specific categories like 10-K, ER, or IR, and is a general corporate announcement regarding company activities, it is classified as a Regulatory Filing (RNS).
2025-12-04 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2025
Regulatory Filings Classification · 95% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for companies listed on the HKEX to report monthly movements in securities, share capital, and treasury shares. It does not fit into specific categories like 'Annual Report' or 'Earnings Release' but is a mandatory regulatory filing for listed entities. Therefore, it is classified as a Regulatory Filing (RNS).
2025-12-04 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.